ストックスクリーナーアプリを入手
4.455
1.89%
0.085
前日終値:
$4.37
開ける：
$4.5
24時間の取引高:
121.96K
Relative Volume:
0.13
時価総額：
$331.96M
収益：
-
当期純損益:
$-27.03M
株価収益率:
-7.9554
EPS:
-0.56
ネットキャッシュフロー:
$-23.97M
1週間 パフォーマンス:
+3.79%
1か月 パフォーマンス:
+7.56%
6か月 パフォーマンス:
-11.65%
1年 パフォーマンス:
+21.00%
1日の値動き範囲:
$4.415
$4.54
1週間の範囲:
$4.051
$4.67
52週間の値動き範囲:
$2.54
$10.00
Corvus Pharmaceuticals Inc Stock (CRVS) Company Profile
名前
Corvus Pharmaceuticals Inc
セクター
電話
(650) 900-4520
住所
863 MITTEN ROAD, BURLINGAME, CA
CRVS を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CRVS
Corvus Pharmaceuticals Inc
|
4.455 | 332.36M | 0 | -27.03M | -23.97M | -0.56 |
|
VRTX
Vertex Pharmaceuticals Inc
|
384.35 | 93.98B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.34 | 59.67B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
431.84 | 57.53B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
644.53 | 40.50B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.85 | 34.26B | 3.81B | -644.79M | -669.77M | -6.24 |
Corvus Pharmaceuticals Inc Stock (CRVS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-01-02 | 開始されました | H.C. Wainwright | Buy |
| 2023-08-18 | 開始されました | Oppenheimer | Outperform |
| 2021-12-01 | 再開されました | Jefferies | Buy |
| 2021-05-27 | 開始されました | Cantor Fitzgerald | Overweight |
| 2021-02-10 | ダウングレード | Mizuho | Buy → Neutral |
| 2019-09-12 | 開始されました | Mizuho | Buy |
| 2019-05-29 | 開始されました | ROTH Capital | Buy |
| 2017-08-24 | アップグレード | Credit Suisse | Underperform → Neutral |
| 2017-05-01 | ダウングレード | Credit Suisse | Neutral → Underperform |
| 2016-04-18 | 開始されました | Credit Suisse | Outperform |
| 2016-04-18 | 開始されました | Guggenheim | Buy |
すべてを表示
Corvus Pharmaceuticals Inc (CRVS) 最新ニュース
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q2 2025 Earnings Call Transcript - Insider Monkey
Long term hold vs stop loss in Corvus Pharmaceuticals Inc.Watchlist Summary for Active Day Traders - Newser
What to expect from Corvus Pharmaceuticals Inc. in the next 30 daysTechnical Analysis of Growth Stock Opportunities - Newser
How Corvus Pharmaceuticals Inc. stock performs during market volatilityStocks That Can Explode Soon - thegnnews.com
What makes Corvus Pharmaceuticals Inc. stock price move sharplyMomentum Stocks with Breakout Potential - Newser
How to forecast Corvus Pharmaceuticals Inc. trends using time seriesMarket Correction Proof Stock Screening Analysis - Newser
Advanced analytics toolkit walkthrough for Corvus Pharmaceuticals Inc.Smart Risk Strategy with Entry Optimization - Newser
Published on: 2025-08-11 02:13:29 - Newser
Does Corvus Pharmaceuticals Inc. qualify in momentum factor screeningFree Chart Alert System With Entry Targets - Newser
Momentum divergence signals in Corvus Pharmaceuticals Inc. chartFree Triple Digit Return Stock Predictions - Newser
Can volume confirm reversal in Corvus Pharmaceuticals Inc.2-Day Signal Watch with Forecast Outcome - Newser
Is Corvus Pharmaceuticals Inc. stock ready for a breakoutTrend Analysis for Safer Market Entries - Newser
Price action breakdown for Corvus Pharmaceuticals Inc.Free Daily Growth Stock Pick Reports - Newser
Is Now a Good Time to Reenter Corvus Pharmaceuticals Inc.Scalable Portfolio Growth Suggestions Released - beatles.ru
Corvus (CRVS) Q2 Loss Beats Estimates - AOL.com
Real time pattern detection on Corvus Pharmaceuticals Inc. stockTechnical Insight Guide for Safer Trades - Newser
Corvus plans Phase II trial for soquelitinib in atopic dermatitis, targeting 200 patients with 12-week treatment window - MSN
Traders Watching For Reversal Pattern in Corvus Pharmaceuticals Inc.AI Trading Suggestions With Accuracy Focus Released - metal.it
Sentiment analysis tools applied to Corvus Pharmaceuticals Inc.Free Trend Analysis for Safer Trades - Newser
Custom strategy builders for tracking Corvus Pharmaceuticals Inc.Free Pattern Detection for Entry Confirmation - Newser
What recovery options are there for Corvus Pharmaceuticals Inc.Real Chart Based Opportunity Identification - Newser
Transcript : Corvus Pharmaceuticals, Inc., Q2 2025 Earnings Call, Aug 07, 2025 - MarketScreener
Can technical indicators confirm Corvus Pharmaceuticals Inc.’s reversalFree Short Term Setup With Predictive Chart - Newser
Earnings call transcript: Corvus Pharmaceuticals’ Q2 2025 results show EPS beat By Investing.com - Investing.com South Africa
Earnings call transcript: Corvus Pharmaceuticals’ Q2 2025 results show EPS beat - Investing.com
Corvus Pharmaceuticals Inc (CRVS) Q2 2025 Earnings Call Highlights: Strategic Advances Amid ... By GuruFocus - Investing.com Canada
Published on: 2025-08-08 00:04:14 - Newser
Corvus Pharmaceuticals Reports Q2 2025 Progress and Financials - TipRanks
Corvus Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Institutional scanner results for Corvus Pharmaceuticals Inc.Free Reliable Alerts for Daily Stock Movers - Newser
Corvus: Q2 Earnings Snapshot - San Francisco Chronicle
Corvus Reports Breakthrough: New Atopic Dermatitis Drug Shows Powerful 65% Disease Reduction in Phase 1 Trial - Stock Titan
Corvus Pharmaceuticals Inc (CRVS) 財務データ
収益
当期純利益
現金流量
EPS
0.21%
2.88%
大文字化:
|
ボリューム (24 時間):